122 related articles for article (PubMed ID: 10147051)
1. The costs and benefits of switching a drug from prescription-only to over-the-counter status: a review of methodological issues and current evidence.
Andersson F; Hatziandreu E
Pharmacoeconomics; 1992 Nov; 2(5):388-96. PubMed ID: 10147051
[TBL] [Abstract][Full Text] [Related]
2. The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis.
Shih YC; Prasad M; Luce BR
Clin Ther; 2002 Apr; 24(4):701-16. PubMed ID: 12017413
[TBL] [Abstract][Full Text] [Related]
3. Assessing the economic impact of Rx-to-OTC switches: systematic review and guidelines for future development.
Cohen J; Millier A; Karray S; Toumi M
J Med Econ; 2013; 16(6):835-44. PubMed ID: 23597040
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing pharmacists' preference for the legal classification of Rx-to-OTC switched drug products.
Madhaven S
J Clin Pharm Ther; 1993 Aug; 18(4):281-90. PubMed ID: 8227236
[TBL] [Abstract][Full Text] [Related]
5. Costs and benefits in switching from Rx to OTC.
Temin P
J Health Econ; 1983 Dec; 2(3):187-205. PubMed ID: 10310393
[TBL] [Abstract][Full Text] [Related]
6. The influence of Rx-to-OTC changes on drug sales. Experiences from Sweden 1980-1994.
Carlsten A; Wennberg M; Bergendal L
J Clin Pharm Ther; 1996 Dec; 21(6):423-30. PubMed ID: 9201570
[TBL] [Abstract][Full Text] [Related]
7. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
Sullivan PW; Nair KV; Patel BV
Am J Manag Care; 2005 Jun; 11(6):374-82. PubMed ID: 15974556
[TBL] [Abstract][Full Text] [Related]
8. Dispensing physicians and prescribing pharmacists: economic considerations for the UK.
Ryan M; Bond C
Pharmacoeconomics; 1994 Jan; 5(1):8-17. PubMed ID: 10146862
[TBL] [Abstract][Full Text] [Related]
9. Switching of prescription drugs to over-the-counter status: is it a good thing for the elderly?
Francis SA; Barnett N; Denham M
Drugs Aging; 2005; 22(5):361-70. PubMed ID: 15903349
[TBL] [Abstract][Full Text] [Related]
10. American Pharmaceutical Association review of literature on prescription to over-the-counter drug switches.
Schulke DG
Clin Ther; 1998; 20 Suppl C():C124-33. PubMed ID: 9915099
[TBL] [Abstract][Full Text] [Related]
11. Switching from prescription to over-the counter medications: a consumer and managed care perspective.
Pawaskar MD; Balkrishnan R
Manag Care Interface; 2007 Jan; 20(1):42-7. PubMed ID: 17310652
[TBL] [Abstract][Full Text] [Related]
12. From prescription-only (Rx) to over-the-counter (OTC) status in Germany 2006-2015: pharmacological perspectives on regulatory decisions.
Barrenberg E; Garbe E
Eur J Clin Pharmacol; 2017 Jul; 73(7):901-910. PubMed ID: 28352949
[TBL] [Abstract][Full Text] [Related]
13. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines.
Sullivan PW; Nichol MB
Value Health; 2004; 7(4):402-12. PubMed ID: 15449632
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the movement of prescription drugs to over-the-counter status.
Harrington P; Shepherd MD
J Manag Care Pharm; 2002; 8(6):499-508; quiz 509-11. PubMed ID: 14613383
[TBL] [Abstract][Full Text] [Related]
15. The benefits of switching smoking cessation drugs to over-the-counter status.
Keeler TE; Hu TW; Keith A; Manning R; Marciniak MD; Ong M; Sung HY
Health Econ; 2002 Jul; 11(5):389-402. PubMed ID: 12112489
[TBL] [Abstract][Full Text] [Related]
16. Rx-to-OTC switches: from prescription to self-care.
Newton G; Popovich NG; Pray WS
J Am Pharm Assoc (Wash); 1996 Aug; NS36(8):488-95. PubMed ID: 8783841
[TBL] [Abstract][Full Text] [Related]
17. Consumer preferences for over-the-counter drug retailers in the reregulated Swedish pharmacy market.
Håkonsen H; Sundell KA; Martinsson J; Hedenrud T
Health Policy; 2016 Mar; 120(3):327-33. PubMed ID: 26861972
[TBL] [Abstract][Full Text] [Related]
18. New OTC drugs and devices 2002: a selective review.
Newton GD; Pray WS; Popovich NG
J Am Pharm Assoc (Wash); 2003; 43(2):249-60. PubMed ID: 12688440
[TBL] [Abstract][Full Text] [Related]
19. Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.
Tasch RF; Goeree R; Henke CJ; O'Brien BJ
Pharmacoeconomics; 1996 Jan; 9(1):61-75. PubMed ID: 10160088
[TBL] [Abstract][Full Text] [Related]
20. The effect of generic competition on prescription to over-the-counter switching.
Hollenbeak CS
Pharmacoeconomics; 1999 Dec; 16(6):661-8. PubMed ID: 10724793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
